We retrospectively reviewed the clinical data of 388 eligible patients with advanced non-squamous NSCLC harboring EGFR mutations treated with EGFR-TKIs as 1st-line therapy, which were collected from five medical institutions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.